Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

References

• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• YangJWangXFuhGComparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor AMol Pharm201411103421343025162961
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol2007143456658317386270
   PubMed Web of Science ®Google Scholar
• GuptaOPShienbaumGPatelAHFecarottaCKaiserRSRegilloCDA treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impactOphthalmology2010117112134214020591490
   PubMed Web of Science ®Google Scholar
• MantelINiderprimSAGianniouCDeliAAmbresinAReducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimenBr J Ophthalmol20149891192119624729031
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• ChakravarthyUHardingSPRogersCAIVAN study investigatorsAlternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialLancet201338299001258126723870813
   PubMed Web of Science ®Google Scholar
• IVAN Study InvestigatorsChakravarthyUHardingSPRanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trialOphthalmology201211971399141122578446
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
   PubMed Web of Science ®Google Scholar
• GianniouCDiraniAFerriniWTwo-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional resultsEye (Lond)201529334234925359289
   PubMed Web of Science ®Google Scholar
• MantelIDeliAIglesiasKAmbresinAProspective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2013251369770422733165
   PubMed Web of Science ®Google Scholar
• KeanePALiakopoulosSOngchinSCQuantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degenerationInvest Ophthalmol Vis Sci20084973115312018408176
   PubMed Web of Science ®Google Scholar
• EghojMSSorensenTLTachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumabBr J Ophthalmol2012961212321733918
   PubMed Web of Science ®Google Scholar
• GasperiniJLFawziAAKhondkaryanABevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisationBr J Ophthalmol2012961142021791509
   PubMed Web of Science ®Google Scholar
• SchaalSKaplanHJTezelTHIs there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?Ophthalmol20081151221992205
   PubMed Web of Science ®Google Scholar
• ArjamaaOMinnHResistance, not tachyphylaxis or toleranceBr J Ophthalmol201296811531154
   Web of Science ®Google Scholar
• BinderSLoss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?Br J Ophthalmol20129611222157632
   PubMed Web of Science ®Google Scholar
• YangSZhaoJSunXResistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewDrug Des Devel Ther20161018571867
   PubMed Web of Science ®Google Scholar
• de MassougnesSDiraniAAmbresinADecugisDMarchionnoLMantelIPigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effectsRetina201636588188827115852
   PubMed Web of Science ®Google Scholar
• BarthelmesDCampainANguyenPFight Retinal Blindness! Project InvestigatorsEffects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degenerationBr J Ophthalmol2016100121640164526994110
   PubMed Web of Science ®Google Scholar
• SaraoVParravanoMVerittiDAriasLVaranoMLanzettaPIntravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapyRetina201636477077726398691
   PubMed Web of Science ®Google Scholar
• ArcinueCAMaFBarteselliGSharpstenLGomezMLFreemanWROne-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degenerationAm J Ophthalmol20151593426e2436e225461263
   PubMed Web of Science ®Google Scholar
• GrewalDSGillMKSarezkyDLyonATMirzaRGVisual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month resultsEye (Lond)201428789589924833178
   PubMed Web of Science ®Google Scholar
• MessengerWBCampbellJPFaridiAInjection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degenerationBr J Ophthalmol20149891205120724795334
   PubMed Web of Science ®Google Scholar
• KumarNMarsigliaMMrejenSVisual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degenerationRetina20133381605161223549101
   PubMed Web of Science ®Google Scholar
• SchachatAPSwitching anti-vascular endothelial growth factor therapy for neovascular age-related macular degenerationAm J Ophthalmol201315611.e12.e123791369
   PubMed Web of Science ®Google Scholar
• DespreauxRCohenSYSemounOShort-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practiceGraefes Arch Clin Exp Ophthalmol2016254463964426092633
   PubMed Web of Science ®Google Scholar
• SleanGRHemaratKKhuranaRNStewartJMConversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case seriesInt J Retina Vitreous20162227847620
   PubMedGoogle Scholar
• MantelIGianniouCDiraniAConversion to aflibercept therapy versus continuing with ranibizumab therapy for neovascular age-related macular degeneration dependent on monthly ranibizumab treatmentRetina2016361535826166797
   PubMed Web of Science ®Google Scholar
• de MassougnesSDiraniAMantelIGood visual outcome at 1 year in neovascular age-related macular degeneration with pigment epithelium detachment: factors influencing the treatment responseRetina Epub2017330
   Google Scholar
• DiraniAAmbresinAMarchionnoLDecugisDMantelIFactors influencing the treatment response of pigment epithelium detachment in age-related macular degenerationAm J Ophthalmol20151604732.e2738.e226144701
   PubMed Web of Science ®Google Scholar
• SinghRPSrivastavaSKEhlersJPA single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysisClin Ophthalmol201591759176626445522
   PubMedGoogle Scholar
• GianniouCDiraniAJangLMantelIRefractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranibizumab: functional and structural outcomeRetina20153561195120125650710
   PubMed Web of Science ®Google Scholar
• JangLGianniouCAmbresinAMantelIRefractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcomeGraefes Arch Clin Exp Ophthalmol201525381211121625267418
   PubMed Web of Science ®Google Scholar
• WaldsteinSMSimaderCStaurenghiGMorphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW TrialsOphthalmology201612371521152927157149
   PubMed Web of Science ®Google Scholar
• SharmaSTothCADanielEComparison of Age-related Macular Degeneration Treatments Trials Research GroupMacular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trialsOphthalmology2016123486587526783095
   PubMed Web of Science ®Google Scholar
• JaffeGJMartinDFTothCAComparison of Age-related Macular Degeneration Treatments Trials Research GroupMacular morphology and visual acuity in the comparison of age-related macular degeneration treatments trialsOphthalmology201312091860187023642377
   PubMed Web of Science ®Google Scholar
• SimaderCRitterMBolzMMorphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degenerationOphthalmology201412161237124524684838
   PubMed Web of Science ®Google Scholar
• HolzFGTadayoniRBeattySMulti-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBr J Ophthalmol201599222022625193672
   PubMed Web of Science ®Google Scholar
• RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
   PubMed Web of Science ®Google Scholar